HomeRecall LibraryMedication RecallsInitial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib)
FDA recall notice

Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib)

Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib)

What to do next

Read the issuing agency's notice carefully, compare the product identifiers, and follow the official remedy instructions. RecallDefense helps you keep watch, but the source agency's notice is the authority for action.

View source notice

Source attribution: FDA. Published Feb 4, 2021.

Continue Exploring Recall Coverage

Keep Watch After Today

Save a product and get notified when a new recall matches it.

Start Monitoring Free